drugset / Trial / NCT01210898

Immunogenicity and Safety of V70P5 Revaccination Subjects

NCT01210898 ↗

Phase 3 Completed 197 enrolled Novartis Vaccines
RandomizedParallel-groupSingle-blindPrevention

Summary

This study will evaluate the safety and immunogenicity of children previously primed in the V70P5 study when revaccinated with adjuvanted or unadjuvanted seasonal influenza vaccine.

Timeline

Start
2010-09
Primary completion
2011-01
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject MF59-adjuvanted TIV Vaccine — Intramuscular

Indications